Pennsylvania-based integrated health system Geisinger is partnering with an Israel-based company that has developed machine learning-based solutions to aid in early detection and prevention of high-burden diseases.
Partnering with Geisinger's Steele Institute for Health Innovation, Medial EarlySign will deploy its LGI-Flag solution to help Geisinger healthcare practitioners identify patients who are at risk for significant lower gastrointestinal (GI) disorders. LGI-Flag analyzes medical data, including changes in routine blood tests, to flag those who would benefit from further evaluation.
"Leveraging Geisinger's performance as a national leader in healthcare and its culture of innovation with EarlySign's expertise in machine learning and data analytics will enable us to identify, evaluate and intervene with high-risk patients earlier," said Karen Murphy, Ph.D., R.N., executive vice president and chief innovation officer at Geisinger, in a prepared statement. "This collaboration will help us potentially save lives and improve the care we provide patients by deepening our experience with AI and identifying new ways to integrate it into daily clinical care."
LGI-Flag has been used in healthcare systems since 2015 to identify patients at risk for lower GI disorders associated with chronic occult bleeding. The technology will form the basis for Geisinger and EarlySign to address similar opportunities with other acute and chronic diseases. The partners said they would benefit from Geisinger's innovation infrastructure, unique data assets and world-class care teams.
"EarlySign's technology and the LGI-Flag solution will potentially assist our teams to more quickly identify significant lower GI disorders and intervene earlier than we historically have been able to," said Keith A. Boell, D.O., associate chief quality officer at Geisinger, in a statement. "We look forward to advancing our use of this technology while leveraging our experience to help more patients benefit from these life-changing medical advances."
Founded in 2009, Medial EarlySign is headquartered in Tel Aviv, Israel, with U.S. headquarters in Boston.
